Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B Journal Article
| Authors: | Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Galvez, C. C.; Smit, E. F.; Garassino, M.; Veillon, R.; Baz, D. V.; Pradera, J. F.; Sereno, M.; Kozuki, T.; Kim, Y. C.; Yoo, S. S.; Han, J. Y.; Kang, J. H.; Son, C. H.; Choi, Y. J.; Stroh, C.; Juraeva, D.; Vioix, H.; Bruns, R.; Otto, G.; Johne, A.; Paik, P. K. |
| Article Title: | Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B |
| Abstract: | High-level MET amplification (METamp) is a primary driver in ∼1%–2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor, in patients with advanced NSCLC with high-level METamp who were enrolled by liquid biopsy. While the study was halted before the enrollment of the planned 60 patients, the results of 24 enrolled patients are presented here. The objective response rate (ORR) is 41.7% (95% confidence interval [CI], 22.1–63.4), and the median duration of response is 14.3 months (95% CI, 2.8–not estimable). In exploratory biomarker analyses, focal METamp, RB1 wild-type, MYC diploidy, low circulating tumor DNA (ctDNA) burden at baseline, and early molecular response are associated with better outcomes. Adverse events include edema (composite term; any grade: 58.3%; grade 3: 12.5%) and constipation (any grade: 41.7%; grade 3: 4.2%). Tepotinib provides antitumor activity in high-level METamp NSCLC (ClinicalTrials.gov: NCT02864992). © 2023 The Authors |
| Keywords: | adult; cancer chemotherapy; clinical article; controlled study; human tissue; treatment response; aged; overall survival; genetics; clinical feature; clinical trial; constipation; bevacizumab; cisplatin; diarrhea; drug efficacy; drug safety; drug withdrawal; treatment duration; paclitaxel; biomarkers; biological marker; carboplatin; cancer immunotherapy; edema; progression free survival; quality of life; gene amplification; anemia; nausea; vomiting; carcinoma, non-small-cell lung; lung neoplasms; cohort analysis; antineoplastic activity; pyrimidines; docetaxel; abdominal pain; asthenia; coughing; dyspnea; fever; confidence interval; lung tumor; oncogene; hypoalbuminemia; adverse outcome; tumor burden; pyrimidine derivative; pemetrexed; non-small cell lung cancer; disease exacerbation; oncogene myc; diploidy; scatter factor receptor; tegafur; non small cell lung cancer; met amplification; met gene; rb1 gene; nivolumab; met inhibitor; ramucirumab; humans; human; male; female; article; circulating tumor dna; pembrolizumab; atezolizumab; liquid biopsy; tepotinib; european organization for research and treatment of cancer quality of life questionnaire core 30; european quality of life 5 dimensions questionnaire; european quality of life 5 dimensions 5 level questionnaire; hypoproteinemia; productive cough |
| Journal Title: | Cell Reports Medicine |
| Volume: | 4 |
| Issue: | 11 |
| ISSN: | 2666-3791 |
| Publisher: | Cell Press |
| Date Published: | 2023-11-21 |
| Start Page: | 101280 |
| Language: | English |
| DOI: | 10.1016/j.xcrm.2023.101280 |
| PUBMED: | 37944528 |
| PROVIDER: | scopus |
| PMCID: | PMC10694660 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
